Catalyx Report Uncovering Bottlenecks in Life Sciences Production
A recent report published by Catalyx has brought to light the enduring bottlenecks in manufacturing operations within the life sciences industry. Despite the growing emphasis on digital technology, a striking 63% of pharmaceutical and medical device companies still rely on manual processes for critical production line changes. This reliance on outdated methods underscores a significant gap between technological advancements and real-world applications in manufacturing.
The 2025 Life Sciences Line Clearance Benchmark Report, detailing the production practices and trends within this highly regulated sector, reveals that traditional methods are still predominant among firms.
Ongoing Challenges with Line Clearance
Line clearance, which is a crucial quality assurance process, ensures that production equipment is properly cleaned and set up between product batches to prevent cross-contamination. Unfortunately, it remains a major bottleneck for many organizations. According to the study, an alarming 70% of companies experienced at least one line clearance failure in the past twelve months, with 30% reporting six or more failures. These statistics show little change in comparison to 2023, indicating that the industry has made little progress in addressing these persistent issues.
Mario L. Rocci Jr., CEO of Catalyx, emphasized the pressure on companies to maintain high-quality standards and compliance with regulatory requirements. He pointed out, "This study highlights the potential for digital and AI-based systems to transform line clearance from a bottleneck into a driver of operational excellence."
Limited Scaling of Digital Solutions
While almost half of the respondents stated they piloted new line-clearance technologies in 2023, the actual implementation remains largely restricted. As of 2025, only 11% of companies surveyed have successfully digitized key components of their systems. Furthermore, 26% are utilizing hybrid approaches that combine manual and basic digital methods. Yet, traditional paper checklists and manual inspections continue to dominate the sector.
This limitation creates significant inefficiencies, as participants in the study indicated that simple production line changes typically take between 30 minutes and two hours, while more complex changes can exceed four hours. The primary causes of manufacturing disruptions include human errors, equipment setup issues, and overlooked items, as reported by four out of five respondents.
Urgency for Regulatory Evolution
As regulators and business leaders collaborate to develop appropriate frameworks for the adoption of AI technologies, there is an emerging sense of urgency to adapt traditional line-clearance methods to meet future expectations for oversight, transparency, and data management. Dave Taylor, Product Lead at Catalyx, remarked, "Once this framework is finalized, digitization will become a regulatory requirement aimed at enhancing quality. Organizations focusing on digital solutions not only boost their efficiency but also prepare for a future where regulators expect greater transparency and data integrity."
About the Study
The second benchmark study on line clearance was conducted by Catalyx in the summer of 2025, encompassing over 20,000 professionals globally, following an inaugural study in 2023. This comprehensive research sheds light on current practices and trends surrounding line clearance in the life sciences sector worldwide. For more details, you can access the full report on the
Catalyx website.
Conclusion
Catalyx, with over 30 years of experience in optimizing operations for the life sciences and other highly regulated industries, continues to leverage its global team of over 550 engineers and technology specialists to drive efficiency and compliance. With more than 3,000 projects completed in this sector, Catalyx is at the forefront of efforts to enhance operational performance, ensuring not only productivity but also safety in manufacturing processes.